José Ballarín

José Ballarín

Auto-generated profile, based on publicly available information

José Ballarín

Department of Nephrology, Fundación Puigvert, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2019 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
ASAngel M. Sevillano
Angel M. Sevillano
MDMonserrat Diaz
Monserrat Diaz
FCFernando Caravaca-Fontán
Fernando Caravaca-Fontán
CBClara Barrios
Clara Barrios
CBCarmen Bernis
Carmen Bernis
O(on behalf of the Spanish Group for the Study of Glomerular Diseases (GLOSEN)
on behalf of the Spanish Group for the Study of Glomerular Diseases (GLOSEN)
Background and objectives: Some studies suggest that the incidence of IgA nephropathy is increasing in older adults, but there is a lack of information about the epidemiology and behavior of the disease in that age group. Design, setting, participants, & measurements: In this retrospective multicentric study, we analyzed the incidence, forms of presentation, clinical and histologic characteristics, treatments received, and outcomes in a cohort of 151 patients ≥65 years old with biopsy-proven IgA nephropathy diagnosed between 1990 and 2015. The main outcome was a composite end point of kidney replacement therapy or death before kidney replacement therapy. Results: We found a significant increase in the diagnosis of IgA nephropathy over time from six patients in 1990–1995 to 62 in 2011–2015 (P value for trend =0.03). After asymptomatic urinary abnormalities (84 patients; 55%), AKI was the most common form of presentation (61 patients; 40%). Within the latter, 53 (86%) patients presented with hematuria-related AKI (gross hematuria and tubular necrosis associated with erythrocyte casts as the most important lesions in kidney biopsy), and eight patients presented with crescentic IgA nephropathy. Six (4%) patients presented with nephrotic syndrome. Among hematuria-related AKI, 18 (34%) patients were receiving oral anticoagulants, and this proportion rose to 42% among the 34 patients older than 72 years old who presented with hematuria-related AKI. For the whole cohort, survival rates without the composite end point were 74%, 48%, and 26% at 1, 2, and 5 years, respectively. Age, serum creatinine at presentation, and the degree of interstitial fibrosis in kidney biopsy were risk factors significantly associated with the outcome, whereas treatment with renin-angiotensin-aldosterone blockers was associated with a lower risk. Immunosuppressive treatments were not significantly associated with the outcome. Conclusions: The diagnosis of IgA nephropathy among older adults in Spain has progressively increased in recent years, and anticoagulant therapy may be partially responsible for this trend. Prognosis was poor. Podcast: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2019_07_16_CJASNPodcast_19_08_.mp3

1 February 2005 in Kidney International
Verified
Journal Article
Closed access
PFPatricia Fernandez-Llama
Patricia Fernandez-Llama
SAShana Ageloff
Shana Ageloff
GFGuillermo Fernández-Varo
Guillermo Fernández-Varo
JRJosefa Ros
Josefa Ros
XWXiaoyan Wang
Xiaoyan Wang
WJWladimiro Jiménez
Wladimiro Jiménez

17 May 2016 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Open access
JBJordi Bover
Jordi Bover
PUPablo Antonio Ureña-Torres
Pablo Antonio Ureña-Torres
MLMaria Jesús Lloret
Maria Jesús Lloret
CRC. Ruiz
C. Ruiz
IDI. DaSilva
I. DaSilva
JBJ. Ballarin
J. Ballarin
Introduction: Chronic kidney disease-mineral and bone disorders (CKD-MBD) are associated with costly complications and dismal hard-outcomes. Areas covered: In two comprehensive articles we review contemporary and future pharmacological options for treatment of phosphate (P) imbalance (part 1) and hyperparathyroidism (this part 2), taking into account CKD-accelerated cardiovascular calcification (CVC) processes. Expert opinion: Improvements in CKD-MBD require an integral approach, addressing all three components of the CKD-MBD triad. Here, initial guidance to control hyperparathyroidism is provided, taking into account the presence/absence of CVC. We include also measures for patients at risk of adynamic bone disease or suffering from calciphylaxis. Many epidemiological studies (relating to vitamin D) and thorough analyses of recent randomized clinical trials (of cinacalcet) point towards benefits of attempting to improve biochemical parameters while trying to, at least, avoid progression of CVC by more rational use of intestinal P-binders and low-dose vitamin D derivatives and/or calcimimetics. This approach does not seem to be far away from significantly improving hard-outcomes, at least in the dialysis population. The availability of new drugs and the performance of randomized clinical trials should ultimately lead to define earlier, clearer, and more cost-effective patient stratification and biochemical targets with consequent significant clinical improvements.

1 November 1996 in Kidney International
Verified
Journal Article
Closed access
AFAndreu Ferrer-Martínez
Andreu Ferrer-Martínez
Antonio FelipeAntonio Felipe
Antonio Felipe
PBPedro Barceló
Pedro Barceló
FCFrancisco J. Casado
Francisco J. Casado
JBJosé Ballarín
José Ballarín
MPMarçal Pastor-Anglada
Marçal Pastor-Anglada

1 March 2009 in Journal of Renal Care
Verified
Journal Article
Closed access
PDF file
JBJordi Bover
Jordi Bover
NFNeus Farré
Neus Farré
EAEnric Andrés
Enric Andrés
CCCristina Canal
Cristina Canal
MOMaría Teresa Olaya
María Teresa Olaya
JBJosé Ballarín
José Ballarín

1 August 2013 in Clinical Nephrology
Verified
Journal Article
Closed access
ECElisabet Coll
Elisabet Coll
ESElitsa Stoyanova
Elitsa Stoyanova
LRLara Rodríguez-Ribera
Lara Rodríguez-Ribera
MSMiriam Solozábal
Miriam Solozábal
SPSusana Pastor
Susana Pastor
RMRicard Marcos
Ricard Marcos
Hemodialysis (HD) patients present an enhanced mortality. Since oxidative DNA damage can be considered a biomarker of genomic instability our aim was to evaluate the influence of this genetic biomarker in all-cause mortality in a group of HD patients followed for 4 years. 123 chronic HD patients were included. Overall genomic damage was analyzed using the Comet assay. Oxidative DNA damage was measured using the Comet assay complemented with the use of Endo-III and FPG enzymes. Follow-up was carried out from January 2007 to July 2011. Selected HD patients had a mean age of 62 ± 15 years. During the follow-up 36% of patients died (48% due to cardiovascular disease) and 23% were transplanted. Older patients, with high CRP levels, low levels of cholesterol-HDL and albumin, and higher genetic damage at the beginning of the study showed an increased risk for mortality. Multivariate analysis showed that only genomic damage, age and CRP were independently associated with mortality. Our study shows for the first time that, in HD patients, the presence of high levels of genomic damage is a strong predictor of all-cause mortality. This association remains significant after adjustment for relevant covariates.